Evidence map›Paper›PMID 40114372›Full record

ArticleNucleic acids research2025

Light-induced expression of gRNA allows for optogenetic gene editing of T lymphocytes in vivo.

Diego Velasquez Pulgarin, Nathalie Pelo, Lin Ferrandiz, Tilen Tršelič, William A Nyberg, Gary Bowlin, Alexander Espinosa

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. CRISPR and the Future of Cardiac Disease Therapy: A New Genetic Frontier.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Diego Velasquez PulgarinCenter for Molecular Medicine, Department of Medicine (K2), Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Nathalie PeloCenter for Molecular Medicine, Department of Medicine (K2), Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Lin FerrandizCenter for Molecular Medicine, Department of Medicine (K2), Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.
Tilen TršeličCenter for Molecular Medicine, Department of Medicine (K2), Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.
William A NybergDepartment of Medicine (H7), Karolinska Institutet, Karolinska University Hospital, 141 83 Huddinge, Sweden.
Gary BowlinDepartment of Biomedical Engineering, University of Memphis, Memphis, TN 38152, United States.
Alexander EspinosaCenter for Molecular Medicine, Department of Medicine (K2), Karolinska Institutet, Karolinska University Hospital, 171 64 Stockholm, Sweden.ORCID 0000-0003-1107-776X

Funding

CRISPR-based, Stimuli-responsive Logical Gates in Stem Cells for Enthesis Regeneration on Gradient-inducing and Guiding Electrospun TemplatesF31AR072502 · NIAMS · UNIVERSITY OF MEMPHIS · PI VELASQUEZ PULGARIN, DIEGO · 2017 to 2019
$134k
CancerfondenCancerfonden 200992Konung Gustaf V:s och Drottning Victorias FrimurarestiftelseNIAMS NIH HHS F31 AR072502NIH HHS F31AR072502Whitaker Foundation
6 · The paper itself

Abstract

There is currently a lack of tools capable of perturbing genes in both a precise and a spatiotemporal fashion. The flexibility of CRISPR (clustered regularly interspaced short palindromic repeats), coupled with light's unparalleled spatiotemporal resolution deliverable from a controllable source, makes optogenetic CRISPR a well-suited solution for precise spatiotemporal gene perturbations. Here, we present a new optogenetic CRISPR tool (Blue Light-inducible Universal VPR-Improved Production of RGRs, BLU-VIPR) that diverges from prevailing split-Cas design strategies and instead focuses on optogenetic regulation of guide RNA (gRNA) production. We engineered BLU-VIPR around a new potent blue-light activated transcription factor (VPR-EL222) and ribozyme-flanked gRNA. The BLU-VIPR design is genetically encoded and ensures precise excision of multiple gRNAs from a single messenger RNA transcript. This simplified spatiotemporal gene perturbation and allowed for several types of optogenetic CRISPR, including indels, CRISPRa, and base editing. BLU-VIPR also worked in vivo with cells previously intractable to optogenetic gene editing, achieving optogenetic gene editing in T lymphocytes in vivo.

Indexed as

Gene EditingOptogeneticsRNA, Guide, CRISPR-Cas SystemsT-LymphocytesAnimalsCRISPR-Cas SystemsHEK293 CellsHumansLightMiceRNA, CatalyticTranscription FactorsRNA, CatalyticRNA, Guide, CRISPR-Cas SystemsTranscription Factors

Identifiers

PMID40114372
PMCPMC11925727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.